RNAi Therapeutics Overview
Addressing Sustainability of Oligonucleotide Synthesis
ECO Synthesisâ„¢ technology (Enzyme-Catalyzed Oligonucleotide Synthesis) is a proprietary new synthesis platform that is being developed for manufacturing RNA oligonucleotide therapeutics at scale. By replacing crucial chemical processes with enzymatic methods, ECO Synthesisâ„¢ technology is envisioned to address sustainability and scalability challenges of oligonucleotide manufacturing.
Read Whitepaper
ECO Synthesis™ technology is driven by multiple novel enzymes working as a system to synthesize modified nucleic acids efficiently. The core iterative oligo extension cycle leverages a proprietary terminal deoxynucleotidyl transferase (TdT) enzyme engineered to incorporate common 2’-modified nucleotides, including 2’-F, 2’-OMe, and backbone-modified alpha-phosphorothioate nucleotides, critical for therapeutic RNA applications. Deblocking is achieved enzymatically to close the cyclical process.
Shifting the Paradigm for siRNA Synthesis
Our CodeEvolver® technology platform and experience in enzyme manufacturing come together to enable ECO Synthesis™ technology, with a mission to address the manufacturing obstacles of therapeutic oligonucleotides such as small interfering RNA (siRNA) and antisense oligonucleotides (ASO). The technology strives to provide a transformational alternative to phosphoramidite chemistry and the substantial amount of chemical waste produced.
Read Whitepaper